



# BTOG NON-SMOKING LUNG CANCER ESSENTIAL UPDATE

THURSDAY 13TH OCTOBER 2022  
THE VIEW, LINCOLN'S INN FIELDS, LONDON



**Approved for 6 CPD credits from the Federation of the Royal Colleges of Physicians of the United Kingdom (Ref 141815)**

## Programme

08:30	Registration and Refreshments	
Chairs:	Sanjay Popat and Martin Forster	
09:00	Open and Welcome – BTOG Steering Committee Chair	Sanjay Popat
09:05	About Ruth Strauss Foundation – Research Advisory Group Chair	Martin Forster
09:10	My journey	Gini Harrison
<b>Session 1</b>	<b>The needle in the haystack</b>	
Chairs:	Ruth Sharrock and Anna Perkins	
09:20	Epidemiology and data on non-smoking lung cancer	Michael Peake
09:40	What are the barriers to early diagnosis in non-smokers	Georgia Black
10:00	Promoting early diagnosis	Matthew Evison
10:20	Panel	
10:40	Refreshments	
<b>Session 2</b>	<b>Diagnostics: out with the old...</b>	
Chairs:	Beth Sage and Matthew Evison	
11:00	Investigation of persistent respiratory symptoms in non-smokers – which test and when?	Matthew Callister
11:20	Optimizing the quality of Chest X-Ray's	Fergus Gleeson
11:40	The primary care perspective: what needs to change	Winnie Kwan
12:00	Panel	
12:20	Lunch	
<b>Session 3</b>	<b>Diagnostics: in with the new...</b>	
Chairs:	Fiona Blackhall and Eric Lim	
13:00	The ideal tissue acquisition pathway in a non-smoker?	Justin Garner
13:20	What's a full pathological assessment in a non-smoker?	Andrew Nicholson
13:40	Optimal diagnostic pathway when driver suspicion is high	Hazel O'Sullivan
14:00	Panel	
14:20	Refreshments	
<b>Session 4</b>	<b>Treatments: implementing the future</b>	
Chairs:	Marie Eaton and Matthew Hatton	
14:40	My journey	Alix Burnard
14:50	Diversity of targeted therapies in non-smoking lung cancer	Tom Newsom-Davis
15:10	How to identify and treat the oligos	Kevin Franks
15:30	Supporting patients living with non-smoking lung cancer	Sarah Ivey
15:50	Never smoking lung cancer; the NCRI strategy	Frank McCaughan
16:00	Panel	
16:20	Closing Remarks	Martin Forster
16:30	Close	

## Biographies

**Georgia Black** is a psychologist and applied health researcher in the Department of Applied Health Research at University College London, UK. Georgia's research programme covers patient communication and safety in early diagnosis of cancer, as well as exploring access and inequalities. Georgia has developed a programme of research addressing multiple aspects of cancer diagnosis such as emergency pathways, educational differences in relation to cancer, psychological impact of and fear of cancer, and public attitudes to changes in cancer policy.

**Fiona Blackhall** is Professor of Thoracic Oncology and Honorary Consultant in Medical Oncology - she was educated at St Andrews and Manchester Universities. She began Medical Oncology training at The Christie in 1995 and was awarded a four-year Cancer Research Campaign Research PhD Fellowship for a Clinician in 1997 at the Paterson Institute for Cancer Research, Manchester. Following her PhD she undertook a postdoctoral and clinical fellowship in the field of lung cancer and translational research at Princess Margaret Hospital, University of Toronto and Ontario Cancer Institute, Canada. She returned to the UK in 2003 to complete higher specialist training in oncology and was appointed to consultant at The Christie in 2005. Dr Blackhall then established translational research in lung cancer in collaboration with Professor Caroline Dive (CRUK-Manchester Institute). In 2011 this work was recognised with award of the CRUK translational research prize, and in 2012 Dr Blackhall was awarded Christie Hospital Senior Researcher of the year. Since 2005 she has led a clinical trials portfolio of more than 80 phase I-III trials and has been involved in a number of practice-changing studies delivering promising new drugs and treatment regimens to patients. Dr Blackhall is the clinical lead for lung cancer at The Christie and Manchester Cancer Research Centre (MCRC) lung cancer research strategy lead. She is also the Clinical Trials Theme Lead for the recently established Cancer Research UK Lung Cancer Centre of Excellence which is a recognised research partnership between the University of Manchester and University College London. Dr Blackhall's overall objective is to contribute clinically relevant lung cancer research to improve outcomes for lung cancer.

**Alix Burnard** is 29 and was diagnosed with ALK positive lung cancer in June 2021. Alix lives in Berkshire and is a patient at the Royal Marsden Hospital. She is a sales manager for an IT vendor but has taken some time out to focus on her health.

**Matthew Callister** is Professor, Consultant Respiratory Physician, St James University Hospital. Prof Callister trained in Oxford, London and Yorkshire and was appointed as a Consultant Respiratory Physician in Leeds in 2008. His research interest is the early detection of lung cancer. He is clinical lead for the Leeds Early Lung Cancer Project and co-chaired the BTS Pulmonary Nodule Guideline.

**Marie Eaton** qualified as a registered nurse from the University of Manchester in 2011 and started her career working in the community and emergency department. While gaining experience in these fields, she completed her BSc (Hons) degree in Adult Nursing. In 2016 she was appointed as a Clinical Nurse Specialist in lung cancer at The Christie Hospital where she has been in post since. During this time, she has obtained her Non-Medical Prescribing qualification and is involved in the autonomous care of patients with never smoking lung cancers through nurse led prescribing clinics. Marie has a keen interest in supporting and caring for patients with lung cancer and their families.

**Matthew Evison** MD, MRCP is Consultant Chest Physician at Wythenshawe Hospital, Manchester University NHS Foundation Trust. He is the clinical lead for the CURE programme and Tobacco Addiction and a core member of the Specialist Lung Cancer and Pleural Teams. This role includes delivery of the CURE, RAPID and Lung Health Check programmes at Wythenshawe Hospital. Also the Director of the Lung Pathway Board and clinical lead for the CURE project for Greater Manchester. Additionally, he is member of the British Thoracic Society Specialist Advisory Groups for Tobacco and Pleural and a member of the British Thoracic Oncology Group Steering Committee.

**Martin Forster** is an associate professor at UCL and consultant medical oncologist at University College Hospital. He specialises in thoracic and head and neck cancers and has a particular interest in drug development and in using the increasing understanding of cancer biology to design studies that distinguish patient populations most likely to gain benefit from new drugs and new drug combinations. He is a core member of the lung and head and neck cancer teams and runs a research-based practice, being principal investigator or chief investigator for over 50 early and late-phase clinical trials, from first-in-human to registration Phase III trials. These include targeted therapies in precision oncology trials, novel immunotherapies, and more recently solid cancer cell therapy studies.

Martin collaborates broadly with national and international groups involved in translational research and is joint lead for the clinical trials theme of the Cancer Research UK Lung Cancer Centre of Excellence and chairs the NIHR Head and Neck Research Group. He is the UCLH clinical lead for chemotherapy services and co-lead for the London Cancer Chemotherapy Expert Reference Group.

**Kevin Franks** is a Thoracic Consultant Clinical Oncologist, Deputy Director for the Leeds NIHR Clinical Research Facility and the Clinical Lead for Oncology Research and Innovation at the Leeds Teaching Hospitals NHS Trust. Following a 2-year research fellowship at the Princess Margaret Hospital/University of Toronto in technical lung cancer radiotherapy he returned to Leeds and was the clinical lead for the team that implemented lung Stereotactic Ablative Radiotherapy (SABR) in Leeds in 2009. Leeds was the first centre in the UK to use this innovative technique and have treated more than 2000 patients since 2009. He was a founder member of the UK SABR Consortium and the ex-chair of the UK SABR Research Sub-Group. He was the co-chair of national guidelines for; National Cancer Action Team (NCAT) Image-Guided Radiotherapy (IGRT) working group -national guidelines (published 2012) and On Target 2: updated guidance for image-guided radiotherapy. Radiotherapy Board (Institute of Physics and Engineering in Medicine/College of Radiographers/Royal College of Radiologists) (published 2021). He is an Associate Professor at the University of Leeds, and his research interests are in Lung Cancer including technical radiotherapy, SABR, cancer informatics, quality of life, patient optimization and novel agent/SABR+RT combinations. He was the chief investigator for the NIHR funded SABRtooth trial or SABR versus Surgery, is the co-chief investigator of the YCR funded PREHAB trial looking at exercise, diet and smoking cessation in curative lung cancer patients receiving radiotherapy and is also involved in many national and international trials in lung cancer RT and SABR including trials of RT combined with novel therapies and trial of new agents/chemotherapy in the advanced disease setting.

**Justin Garner** is a consultant respiratory physician at Royal Brompton Hospital. Dr Garner qualified from Imperial College School of Medicine, UK, in 2008. He trained as a respiratory specialist in the North-West Thames deanery and completed his PhD in Interventional Bronchoscopy under Professors Pallav Shah and Dr Omar Usmani in 2020. He has worked as a consultant respiratory physician at the Royal Brompton Hospital since October 2021.

**Fergus Gleeson** is Professor of Radiology at the University of Oxford, Consultant Radiologist, Head of Academic Radiology, Director of the Oxford Imaging Trials Unit and Divisional Director for the Oxford University Hospitals NHS Trust. Fergus trained in Cambridge, Papworth and London, and was a Fellow in Radiology at UCLA in Los Angeles. He was appointed to Oxford in 1992, and is head of academic radiology, the director of the Oxford Imaging Trials Unit, and a Divisional Director for the Oxford University Hospitals NHS Trust. His specialist interests are in PET and hyperpolarized xenon MRI.

**Dr Gini Harrison** was diagnosed with Stage 4 EGFR+ lung cancer (adenocarcinoma) in December 2021. She is a mother of two young children; a Chartered Psychologist specialising in perinatal mental health; and a Senior Lecturer at the Open University.

**Matthew Hatton** is Honorary Professor in Clinical Oncology/Consultant and Honorary Reader in Oncology at University of Sheffield/Weston Park Hospital. He graduated from Leeds where he completed his general medical training. He undertook his specialist oncology training at the Beatson Oncology Centre in Glasgow before taking his current post at Weston Park in 1997. Dr Hatton was appointed as Honorary Professor at the University of Sheffield in 2016 and is the current Chair of the National Cancer Research Institute Lung Cancer Study Group. He serves on the International Association for the Study of Lung Cancer Education Board. His research interests include functional imaging for radiotherapy planning, novel radiotherapy applications and fractionations being Chief Investigator for a number of national lung cancer, sarcoma and cardiac radiotherapy studies.

**Sarah Ivey** is the Team leader for the Lung Cancer CNS teams at Frimley Park Hospital and Wexham Park Hospital. Sarah's early career was spent in intensive care before moving into community nursing. Sarah specialised in palliative care working first as a hospice clinical nurse specialist before moving back into the acute sector. to join a lung cancer team as a Macmillan Clinical Nurse Specialist. Sarah's special areas of interest include research and reaching minority groups to ensure equal access of services to all.

**Winnie Kwan** has been working as a GP in South-East London since 1989. Dr Kwan has been a Macmillan GP since 2005, the GP Clinical Lead for Cancer for Bexley since 2007, now part of the South-East London Integrated Care System, and GP Clinical Lead for South-East London Cancer Alliance since 2019.

**Eric Lim** is Consultant thoracic surgeon, Senior lecturer and reader of thoracic surgery, Imperial College London, Professor of Thoracic surgery, Imperial College London. Based at Royal Brompton Hospital and a professor of thoracic surgery at Imperial College London. Mr Eric Lim studied at the University of Sheffield and trained in cardiothoracic surgery in Cambridge and London. He was the recipient of an MRC scholarship and was awarded an MSc in Biostatistics and an MD for surgical research. Mr Lim joined the Royal Brompton Hospital in 2007 as a consultant thoracic surgeon and leads the hospital's Cancer Research Consortia. Mr Lim specialises in thoracic surgical diseases, with a strong focus on patient care, aspiring to make thoracic surgery that causes the least amount of pain and disruption to the patient's life as possible. Holding leadership positions both nationally and internationally places Mr Lim at the forefront of his speciality, providing balanced and authoritative opinions on patient and clinical care for patients with advanced lung cancer, where surgery is being considered or when patients who have been declined surgery because they were considered too high risk.

**Frank McCaughan** is Wellcome Trust Intermediate Clinical Fellow / Honorary Consultant at University of Cambridge and Cambridge University Hospitals NHS Trust

**Tom Newsom-Davis** is a consultant in medical oncology at Chelsea and Westminster Hospital where he specialises in thoracic malignancies. He set up and leads the Chelsea and Westminster Acute Oncology Unit and chairs the London Cancer Alliance Acute Oncology Group. Dr Newsom-Davis has an active clinical trials portfolio for both the National Cancer Research Network and commercial lung cancer studies. He is Divisional Lead for Research at Chelsea and Westminster and is a member of the National Cancer Research Institute's lung cancer clinical study group. Dr Newsom-Davis has led a number of acute oncology research projects, including the development of an acute oncology eLearning course and an app. He has presented his work at a national and international level, and has been an invited lecturer for various organisations including the Royal College of Physicians, British Medical Association and the Association of Cancer Physicians.

**Professor Andrew Nicholson** is a consultant histopathologist specialising in thoracic pathology, and an honorary professor of respiratory pathology at the National Heart and Lung Institute, Imperial College London. He has particular expertise in thoracic pathology (lung and mediastinum) and conducts research into lung cancer and interstitial lung disease in particular. He reports between 200 and 300 referrals from clinicians and other pathologists, nationally and internationally, each year.

**Hazel O'Sullivan** MB Bch BAO MRCPI is a Clinical Research Fellow at The Royal Marsden NHS Foundation Trust

**Professor Michael Peake OBE** is Clinical Co-Director of the Centre for Cancer Outcomes, University College London Hospitals, Specialist Advisor to Cancer Research UK, Hon. Professor of Respiratory Medicine, University of Leicester and Hon. Clinical Lead in the National Cancer Registration and Analysis Service. He established the National Lung Cancer Audit and the UK Lung Cancer Coalition, co-founded Mesothelioma UK and the British Thoracic Oncology Group. He has been involved in national cancer policy since the 1990s and published widely, major interests being early cancer diagnosis and improving outcomes for patients by proper service configuration, supported by clinical outcome data. He was awarded an OBE in the Queen's Birthday Honours list in 2020 for his services to medicine.

**Anna Perkins** is Communications and Engagement Lead at Greater Manchester Cancer Alliance where she is responsible for all external-facing communications, with a particular focus on the development and delivery of early diagnosis campaigns for the public. She is also responsible for patient and public involvement, leading the Alliance's long-established User Involvement Programme to ensure public and patient voices are represented and considered in the Alliance's work. Prior to her role at the Cancer Alliance, Anna was responsible for leading the national roll-out of GatewayC, an online cancer education platform for primary care, designed to support healthcare professionals to improve the quality of their referrals and detect cancer at the earliest opportunity. During her time working in the communications industry, Anna has worked across health, oncology and transport sectors, covering a range of specialisms including crisis communications, public affairs, media and public campaigns.

**Professor Sanjay Popat** BSc MBBS FRCP PhD is a Consultant Medical Oncologist at The Royal Marsden, Professor of Thoracic Oncology at the Institute of Cancer Research and is an internationally recognized expert in the treatment of lung cancer, mesothelioma and cancers of the thymus (thymoma and thymic carcinoma). Professor Popat qualified in 1994 from Guy's and St Thomas' Hospitals with triple distinction and was awarded a PhD in Molecular Genetics in 2002, undertaking a postdoctoral Clinician Scientist Fellowship and a HEFCE Clinical Senior Lectureship thereafter. Professor Popat has been awarded nationally and internationally competitive prizes for his research, in addition to four research fellowships. His research interests include the complexities of genetic profiling in cancer, as well as developing novel drug treatments through clinical trials. He also holds several national and international roles. Nationally, Professor Popat Chairs the British Thoracic Oncology Group (BTOG) Steering Committee, is Co-Director for the NIHR London South Clinical Research Network Cancer Division, the NIHR Lung Cancer National Specialty Lead and is past Sub-group Chair of the NCRI Lung Group. Internationally, he sits on the Foundation Council of the European Thoracic Oncology Platform (ETOP) and is active in the European Society of Medical Oncology (ESMO) where he has co-authored European Clinical Practice Guidelines for Small Cell Lung Cancer, Non-Small Cell Lung Cancer, and Mesothelioma. His research collaborations with industry have led to licensing of several drugs globally, leading to implementation in International treatment guidelines and NHS funding approvals. Professor Popat is often an invited Clinical Expert to the National Institute for Health and Care Excellence (NICE) and sits on several committees overseeing the safety and governance for ongoing UK and international clinical trials. Sanjay is a strong advocate for patient education and support and is clinical advisor to several patient-facing cancer charities.

**Dr Beth Sage** is a Consultant Respiratory physician at Raigmore Hospital, Inverness and Honorary Senior Lecturer at the University of Aberdeen. She has a specialist interest in mesothelioma, lung cancer and pleural disease. She won a Medical Research Council Fellowship to complete a PhD in novel therapies for malignant mesothelioma at UCL which she completed in 2013. Beth is clinical lead for lung cancer and has a research interest in early diagnosis of thoracic malignancies and improving access to cancer services in remote and rural populations. She is Director of Research, Development and Innovation at NHS Highland and a Co-Investigator on clinical trials looking at genetically modified cell therapies in thoracic malignancies. She is part of the Scottish Mesothelioma Network, the North Cancer Alliance Lung Pathway Board, is on the Scientific Research Committee for the British Lung Foundation and an Associate Editor for Thorax.

**Ruth Sharrock** Consultant Respiratory Physician and Lung Cancer Clinical Lead, Queen Elizabeth Hospital Gateshead, North East and North Cumbria ICS Tobacco Dependency Clinical Lead and Clinical lead for Gateshead Targeted Lung Health Check Screening Program (Part of Newcastle Gateshead pilot site.)

### Sponsors

**Sponsors have not been involved or influenced the content and the agenda of the meeting.**

